These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 28076404)
1. Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure. Grois L; Hupf J; Reinders J; Schröder J; Dietl A; Schmid PM; Jungbauer C; Resch M; Maier LS; Luchner A; Birner C PLoS One; 2017; 12(1):e0169743. PubMed ID: 28076404 [TBL] [Abstract][Full Text] [Related]
2. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639 [TBL] [Abstract][Full Text] [Related]
3. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495 [TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA; Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927 [TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle alterations in tachycardia-induced heart failure are linked to deficient natriuretic peptide signalling and are attenuated by RAS-/NEP-inhibition. Dietl A; Winkel I; Pietrzyk G; Paulus M; Bruckmann A; Schröder JA; Sossalla S; Luchner A; Maier LS; Birner C PLoS One; 2019; 14(12):e0225937. PubMed ID: 31800630 [TBL] [Abstract][Full Text] [Related]
6. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans. Vesterqvist O; Reeves RA Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802 [TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654 [TBL] [Abstract][Full Text] [Related]
12. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. Thomas CV; McDaniel GM; Holzgrefe HH; Mukherjee R; Hird RB; Walker JD; Hebbar L; Powell JR; Spinale FG J Cardiovasc Pharmacol; 1998 Dec; 32(6):902-12. PubMed ID: 9869495 [TBL] [Abstract][Full Text] [Related]
13. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Chen HH; Cataliotti A; Burnett JC Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801 [TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Singh JS; Lang CC Vasc Health Risk Manag; 2015; 11():283-95. PubMed ID: 26082640 [TBL] [Abstract][Full Text] [Related]
16. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103 [TBL] [Abstract][Full Text] [Related]
17. Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics. Varagic J; Susic D; Slama M; Frohlich ED J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):167-74. PubMed ID: 12808490 [TBL] [Abstract][Full Text] [Related]
18. Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure. Cha YM; Redfield MM; Shah S; Shen WK; Fishbein MC; Chen PS Heart Rhythm; 2005 Sep; 2(9):984-90. PubMed ID: 16171755 [TBL] [Abstract][Full Text] [Related]
19. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. Mori J; Zhang L; Oudit GY; Lopaschuk GD J Mol Cell Cardiol; 2013 Oct; 63():98-106. PubMed ID: 23886814 [TBL] [Abstract][Full Text] [Related]
20. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Ferrario CM; Averill DB; Brosnihan KB; Chappell MC; Iskandar SS; Dean RH; Diz DI Kidney Int; 2002 Oct; 62(4):1349-57. PubMed ID: 12234305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]